14,601 IDEXX Laboratories, Inc. $IDXX Shares Sold by Congress Asset Management Co.

Congress Asset Management Co. cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.7% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 175,592 shares of the company’s stock after selling 14,601 shares during the quarter. Congress Asset Management Co.’s holdings in IDEXX Laboratories were worth $91,692,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of IDXX. Horizons Wealth Management acquired a new position in IDEXX Laboratories during the 3rd quarter worth approximately $52,000. CX Institutional bought a new stake in shares of IDEXX Laboratories during the third quarter worth $338,000. QRG Capital Management Inc. grew its stake in shares of IDEXX Laboratories by 16.8% during the second quarter. QRG Capital Management Inc. now owns 3,323 shares of the company’s stock worth $1,749,000 after buying an additional 477 shares during the last quarter. Envestnet Portfolio Solutions Inc. increased its holdings in shares of IDEXX Laboratories by 2.7% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 28,991 shares of the company’s stock worth $15,262,000 after buying an additional 761 shares in the last quarter. Finally, National Pension Service increased its holdings in shares of IDEXX Laboratories by 5.6% during the second quarter. National Pension Service now owns 129,305 shares of the company’s stock worth $68,071,000 after buying an additional 6,885 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

IDXX has been the topic of several recent research reports. UBS Group raised their price objective on IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Barclays dropped their target price on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, August 27th. Citigroup raised their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Finally, Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Six research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $747.00.

IDEXX Laboratories Trading Down 2.2%

Shares of IDXX traded down $11.66 during mid-day trading on Tuesday, reaching $515.41. 502,349 shares of the company were exchanged, compared to its average volume of 568,822. The business has a 50 day simple moving average of $541.95 and a two-hundred day simple moving average of $554.28. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. The stock has a market capitalization of $40.60 billion, a PE ratio of 36.25, a PEG ratio of 2.77 and a beta of 1.55. IDEXX Laboratories, Inc. has a 52 week low of $500.61 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.94 by $0.33. The firm had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The company’s revenue was up 9.7% compared to the same quarter last year. During the same quarter last year, the business earned $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, analysts predict that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the business’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the transaction, the director owned 9,568 shares in the company, valued at $5,090,941.44. The trade was a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.79% of the stock is owned by corporate insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.

IDEXX’s companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.